retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Eli Lilly's shows promising weight loss results in trial retatrutide is a novel triple
Description
Read more at straitstimes.com
In this randomized clinical trial ...
Conclusions GLP-1RA demonstrated phenotype-specific benefits, improving structural remodeling in HFpEF but showing limited effects in HFrEF
Find the best new GLP-1 drug for you.
Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management
